Ultragenyx ($RARE) Gene Therapy for Rare Liver Ailment Succeeds in Late-Stage Trial

May 30, 2024, 08:51 PM

Ultragenyx's gene therapy for a rare liver ailment has succeeded in a late-stage trial. The therapy, which aims to treat a condition affecting the liver, has shown promising results, marking a significant milestone for the company. The news, reported on May 30, 2024, was covered by multiple sources, including Jason Mast for Stat News. Ultragenyx is listed under the ticker symbol $RARE.